We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
- Authors
Song Ee Park; Jae Myoung Noh; You Jin Kim; Han Sang Lee; Jang Ho Cho; Sung Won Lim; Yong Chan Ahn; Hongryull Pyo; Yoon-La Choi; Joungho Han; Jong-Mu Sun; Se Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
- Abstract
Purpose This study was conducted to evaluate the relationship between epidermal growth factor receptor (EGFR) mutation and clinical outcomes in patients with stage III non-squamous cell lung cancer treated with definitive concurrent chemoradiotherapy (CCRT). Materials and Methods From January 2008 to December 2013, the medical records of 197 patients with stage III non- squamous non-small cell lung cancer treated with definitive CCRT were analyzed to determine progression-free survival (PFS) and overall survival (OS) according to EGFR mutation status. Results Among 197 eligible patients, 81 patients were EGFR wild type, 36 patients had an EGFR mutation (exon 19 Del, n=18; L858R, n=9, uncommon [G719X, L868, T790M], n=9), and 80 patients had unknown EGFR status. The median age was 59 years (range, 28 to 80 years) and 136 patients (69.0%) were male. The median follow-up duration was 66.5 months (range, 1.9 to 114.5 months). One hundred sixty-four patients (83.2%) experienced disease progression. Median PFS was 8.9 months for the EGFR mutation group, 11.8 months for EGFR wild type, and 10.5 months for the unknown EGFR group (p=0.013 and p=0.042, respectively). The most common site of metastasis in the EGFR mutant group was the brain. However, there was no significant difference in OS among the three groups (34.6 months for EGFRmutant group vs. 31.9 months for EGFR wild type vs. 22.6 months for EGFR unknown group; p=0.792 and p=0.284). A total of 29 patients (80.6%) with EGFR mutation were treated with EGFR tyrosine kinase inhibitor (gefitinib, n=24; erlotinib, n=3; afatinib, n=2) upon progression. Conclusion EGFRmutation is associated with short PFS and the brain is the most common site of distant metastasis in patients with stage III non- squamous cell lung cancer treated with CCRT.
- Subjects
EPIDERMAL growth factor receptors; PROGRESSION-free survival; NON-small-cell lung carcinoma; LUNG cancer; SQUAMOUS cell carcinoma
- Publication
Cancer Research & Treatment, 2019, Vol 51, Issue 2, p493
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2018.125